Posts in Capitol Hill

PERA: Where Patent Law and Healthcare Issues Collide

U.S. Supreme Court opinions in Mayo Collaborative Services v. Prometheus Laboratories, Inc., Association for Molecular Pathology v. Myriad Genetics, Inc., and Alice Corporation Pty. Ltd. V. CLS Bank International et al., produced significant challenges to and unpredictability in obtaining and enforcing patent protection in areas including precision medicine, diagnostics, AI, and pharmaceutical treatments. The Patent Eligibility Restoration Act of 2025 (PERA), S. 1546 and the identical H.R. 3152, seek to address these challenges by rewriting 35 U.S.C. § 101 to eliminate all of these “judicial exceptions to patent eligibility.”

Patents Pitted Against PBMs in Senate Judiciary Hearing on U.S. Drug Prices

The full Senate Judiciary Committee today heard from five witnesses who urged senators to take action to curb pharmaceutical industry and pharmacy benefit manager (PBM) practices, which they alternately blamed for high U.S. drug costs. While some senators warned that targeting drug makers could have unintended consequences, most supported moving quickly on legislation they claim would lower prices for U.S. consumers, a claim industry has called a “myth”.

America’s Technology-Neutral Patent System Is a Competitive Advantage: Congress Should Protect It

Congress may soon abandon a principle that has guided the U.S. legal system for generations: the ability to obtain and enforce patent rights should not depend on the type of technology being invented. Straying from this core tenet risks weakening a key competitive advantage of the American innovation economy.

Do Not Let a Paperwork ‘Gotcha’ Sink Valuable Medicines

Congress is considering a bill that would let patents on prescription drugs be rendered unenforceable over an honest paperwork error, even when the underlying invention is genuinely new, non-obvious, and valuable to patients. Supporters of the Medication Affordability and Patent Integrity Act (S. 2658), which the Senate Health, Education, Labor, and Pensions Committee reported in July, say it will lower drug prices by closing what they describe as a loophole that drugmakers use to extend their monopolies.

One Voice, One Law: Artists Need a Federal Voice Right, Not a State-by-State Patchwork

I have spent my career around artists: booking them, interviewing them, publishing their stories and watching how this business treats the people who make it run. Right now the most valuable thing many of those artists own is not a catalog. It is their voice. And in the United States, how well that voice is protected still depends on where you happen to be standing. That has to change. Congress should pass one federal voice-and-likeness right, and it should do it now.

Innovation Alliance Pushes for Trump Admin to Finalize Proposed PTAB Changes

On the eve of the one-year anniversary of the U.S. Patent and Trademark Office’s (USPTO’s) Notice of Proposed Rulemaking (NPRM) to revise the rules of practice for the Patent Trial and Appeal Board (PTAB), the Innovation Alliance is urging the administration to finalize the proposal. The NPRM was published on October 16, 2025, with the aim of focusing inter partes review (IPR) proceedings “on patent claims that have not previously been challenged in litigation or where prior litigation was resolved at an early stage.”

Copyright Office Solicits Comment on Music Streaming Fraud

Today, the U.S. Copyright Office published a notice of inquiry (NOI) in the Federal Register soliciting public comment on issues related to music piracy threatening billions in U.S. domestic revenues generated by digital streaming. The Office’s NOI responds to a request into the prevalence of streaming fraud across the music industry issued by U.S. Representative Scott Fitzgerald (R-WI), who also voiced concerns about generative artificial intelligence’s (AI) impact on the music industry.

When Did Medical Innovation Become a Bad Thing?

Congress has been holding hearings on pharmaceutical patents and drug prices, along with U.S. Patent and Trademark Office (USPTO) fee-setting and oversight. During these hearings, America’s pharmaceutical innovators face an unusual criticism: They are accused of abusing the patent system not only when they invent new medicines, but also when they improve them.

Senate IP Subcommittee Focuses on Fee-Setting, PTAB Rule in USPTO Oversight Hearing

U.S. Patent and Trademark Office (USPTO) Director John Squires faced the Senate Judiciary Committee’s Subcommittee on Intellectual Property Tuesday in an oversight hearing pushing for more information on several of the policy changes his administration has put in place. The hearing was the last over which its current Chairman, Senator Thom Tillis (R-NC), will preside.

D.C. Judge Pauses Perlmutter Suit as Copyright Office Bill Awaits Senate Action

The U.S. District Court for the District of Columbia issued a minute order on September 18, in Perlmutter v. Blanche, staying the lawsuit brought by Register of Copyrights Shira Perlmutter until December 18, 2026. Judge Timothy J. Kelly pointed to the House of Representatives’ June passage of the Legislative Branch Agencies Clarification Act, H.R. 6028, which would designate the Register of Copyrights as an officer “appointed by the President” with the advice and consent of the Senate.

New Bill Would Overhaul Judicial Misconduct Proceedings in Light of Moore-Newman Battle

Representative Scott Fitzgerald (R-WI) has introduced a bill to amend the Judicial Conduct and Disability Act, inspired by U.S. Court of Appeals for the Federal Circuit (CAFC) Judge Pauline Newman’s fight to restore her status as an active judge, following a three-year suspension of her duties initiated by CAFC Chief Judge Kimberly Moore.

Issa Hesitant to Renew USPTO Fee-Setting Authority Amid PTAB Changes

The House Judiciary Committee’s Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet held an oversight hearing today to consider its role in renewing the U.S. Patent and Trademark Office’s (USPTO’s) fee setting authority. Throughout the hearing, Subcommittee Chairman Darrel Issa (R-CA) expressed skepticism about USPTO Director John Squires’ recent changes to discretionary denial practice at the Patent Trial and Appeal Board (PTAB) and wondered whether renewal of such authority under the America Invents Act (AIA) should be conditioned on reforms to the agency’s policy.

From Testimony to Action: Proposed Legislation to Address Issues Raised by Rights Owners During Recent House Hearing

On June 30, 2026, the House Judiciary Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet held a hearing titled, “A Midlife Crisis? IP and the Internet After 40,” which examined whether current U.S. intellectual property laws and enforcement mechanisms are effective against Internet-driven infringement and counterfeiting. The hearing focused on online counterfeiting, digital piracy, and AI-enabled or generated infringement and digital replicas. The hearing also considered the difficulty in enforcing rights against overseas operators, and enforcement tools to address these issues, including Schedule A litigation and website blocking.

Issa Introduces Bill to Name Main CAFC Courtroom after Judge Pauline Newman

Representative Darrell Issa (R-CA), Chairman of the Subcommittee on Intellectual Property, Artificial Intelligence, and the Internet, has introduced a bill to designate courtroom 201 at the Howard T. Markey National Courts Building located at 717 Madison Place NW, Washington, DC, as the “Pauline Newman Courtroom”. Room 201 is the main courtroom of the U.S. Court of Appeals for the Federal Circuit (CAFC).

Congress Said No to Stolen Trademarks; The USPTO Said Yes

On December 31, 1959, Calixto Lopez led armed men into the Arechabala family’s rum distillery in Cárdenas, Cuba. The family had made rum there since 1878, building Havana Club into a brand whose English name reflected its success in the U.S. market. According to testimony Ramón Arechabala gave the Senate Judiciary Committee in 2004, Lopez pointed a machine gun at him and announced he was taking over as “Pepe,” the nickname of the company’s president and Ramón’s uncle. The family’s rum business now belonged to the Cuban government.

Varsity Sponsors

From the IPWatchdog Institute

IPWatchdog Events

IPWatchdog LIVE 2027 at the Renaissance Arlington Capital View
April 4, 2027 @ 1:00 pm - April 6, 2027 @ 7:00 pm EDT
Women’s IP Forum 2027
September 8, 2027 @ 8:00 am - September 10, 2027 @ 5:00 pm EDT
Patent Masters™ 2027
October 6, 2027 @ 8:00 am - October 8, 2027 @ 5:00 pm EDT

From IPWatchdog